10-K: Forte Biosciences Reports Positive Celiac Data, Secures $75M

Forte Biosciences announced positive Phase 1b celiac disease trial data and successfully raised $75 million in a public offering, while continuing to incur significant net losses.

Summary

• Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related indications.
• Positive Phase 1b data for FB102 in celiac disease was announced in June 2025, demonstrating statistically significant benefits on the composite histological VCIEL endpoint (mean change from baseline -1.849 for placebo vs. 0.079 for FB102, p=0.0099).
• FB102 treatment also showed a statistically significant decline in CD3-positive T cells (IELs) from baseline (-1.5 for FB102 vs. +13.3 for placebo, p=0.0035) and a 73% improvement in Vh:Cd ratio compared to placebo.
• Gluten challenge induced GI symptoms reported a 42% benefit for FB102 treated subjects (4.0 events per subject) compared to placebo (6.9 events per subject).
• FB102 demonstrated a good safety profile in Phase 1 healthy volunteer cohorts and the Phase 1b celiac study, with primarily mild (grade 1) treatment emergent adverse events and no grade 3 or higher SAEs reported.
• A Phase 2 celiac study was initiated in July 2025, with topline readout expected in 2026, and the US FDA approved the IND application for a US arm of this study in November 2025.
• Topline data for the Phase 1b non-segmental vitiligo trial is expected in the first half of 2026, and a Phase 1b alopecia areata study has been initiated with topline data expected in 2026.
• The company had approximately $77.0 million in cash and cash equivalents as of December 31, 2025.
• A net loss of $69.4 million was reported for the year ended December 31, 2025, compared to $35.5 million in 2024, contributing to an accumulated deficit of $223.4 million.
• Research and development expenses increased to $58.2 million in 2025 from $21.2 million in 2024, primarily due to increased manufacturing and clinical expenses for FB102 trials.
• General and administrative expenses decreased to $12.4 million in 2025 from $15.4 million in 2024, mainly due to lower professional and legal advisory fees, including litigation and settlement expenses.
• The company successfully defended against a patent challenge from the University of Massachusetts regarding U.S. Patent No. 11,278,505, with the PTAB finding all claims unpatentable in June 2024.
• The company settled legal proceedings with Camac Fund LP for $1.5 million in September 2024 and another related complaint for $650 thousand in October 2024.
• In a legal proceeding against its D&O liability insurers, the Delaware Superior Court entered judgment in favor of Forte Biosciences in January 2026, finding two insurers liable up to $5 million, with an interim payment of $2.3 million received in March 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for a clinical-stage company, driven by promising early clinical data for its lead candidate and successful capital raises that provide a longer runway. While significant losses persist and risks are high, the progress in the pipeline and resolution of a patent challenge are encouraging.

Positives

• Positive Phase 1b clinical data for FB102 in celiac disease, demonstrating statistically significant benefits in key histological and inflammatory endpoints (VCIEL, CD3-positive T cells, Vh:Cd ratio).
• FB102 showed a 42% benefit in reducing gluten challenge induced GI symptoms compared to placebo, indicating symptomatic relief.
• Good safety profile observed for FB102 in Phase 1 and Phase 1b trials, with primarily mild adverse events and no Grade 3 or higher SAEs reported, and no dropouts in the celiac study.
• Successful initiation of a Phase 2 celiac study in July 2025 and Phase 1b studies for non-segmental vitiligo and alopecia areata, indicating pipeline progression.
• FDA approval of the IND application for a US arm of the Phase 2 celiac study, facilitating broader clinical development.
• Successful capital raises in 2025 ($75.0 million public offering, $1.8 million option exercise) and 2024 ($53.0 million private placement), significantly bolstering cash reserves to $77.0 million.
• Successful defense against the University of Massachusetts '505 Patent challenge, with the PTAB finding all claims unpatentable, reducing intellectual property risk.

Negatives

• Significant net loss of $69.4 million for the year ended December 31, 2025, an increase from $35.5 million in 2024.
• Accumulated deficit of $223.4 million as of December 31, 2025, indicating a history of unprofitability.
• The company has no approved products and has not generated any revenue from product sales, relying entirely on capital raises.
• Business is almost entirely dependent on the success of FB102, which is still in early to mid-stage clinical development, posing high inherent risk.
• Will require significant additional capital to fund future operations and complete development and commercialization of FB102, with no committed external sources of funds.
• The market price of common stock is expected to be volatile, having experienced an 82% drop in September 2021 after a previous product candidate (FB-401) trial failure.
• Increased R&D expenses to $58.2 million in 2025 from $21.2 million in 2024 reflect the high and escalating costs of clinical development.
• Exposure to risks from worsening global economic conditions, military conflicts, inflation, rising interest rates, and potential financial institution failures.

Risks

• Will require significant additional capital to fund operations; failure to obtain necessary financing will prevent advancement or completion of clinical development and commercialization of FB102 or future product candidates.
• Business is almost entirely dependent on the success of developing FB102, which may not be successful.
• Results from early preclinical studies and clinical trials may not necessarily be predictive of results from later stage studies or clinical trials.
• No approved products and limited operating history, making it difficult to evaluate technology and predict future performance.
• Incurred net losses in every year since inception and anticipates continued net losses.
• Ability to successfully develop any product candidate is highly uncertain.
• Clinical development is a lengthy and expensive process with an uncertain outcome; may incur additional costs or experience delays.
• Planned preclinical studies, clinical trials, or future clinical trials may reveal significant adverse events, inhibiting regulatory approval or market acceptance.
• Interim top-line and preliminary data may change as more patient data become available and are subject to audit and verification.
• Market opportunities for FB102 may be limited, and estimates of target patient populations may be inaccurate.
• Early in development efforts; FB102 requires significant additional clinical development before seeking regulatory approval.
• Inability to obtain and maintain patent protection for product candidates could allow competitors to commercialize similar products.
• Reliance on third parties to conduct preclinical studies, clinical trials, and manufacturing.
• Market price of common stock is expected to be volatile; risk of class action securities litigation.
• Material weaknesses in or failure to maintain effective internal control over financial reporting could adversely affect investor confidence.
• Operations and financial results could be adversely impacted by public health emergencies or other disruptions.
• Need to grow the size of the organization and may experience difficulties in managing this growth.
• Current operations in Texas; adverse effects from natural disasters, pandemics, or other events out of control.
• Loss of key management personnel or failure to recruit additional highly skilled personnel.
• Internal computer systems, or those used by CROs/CMOs, may fail or suffer security breaches.
• Employees, contractors, consultants, commercial partners, and vendors may engage in misconduct or improper activities.
• Risks associated with testing and developing a product candidate internationally.
• No marketing and sales organization; inability to establish capabilities or agreements with third parties.
• Tax reform legislation could adversely affect business and financial condition.
• Ability to use net operating losses and R&D credits may be subject to limitations.
• Unstable market and economic conditions, including adverse developments affecting the financial services industry, may have serious adverse consequences.
• Changes in United States trade policy, with regard to tariffs, could have a material adverse impact.
• Loss of ability to operate in Australia or benefit from R&D tax rebates could harm business.
• Changes in the legal and regulatory environment could limit future business activities, increase costs, reduce demand, or result in litigation.
• Product candidate, FB102, or any future product candidate, may cause undesirable side effects or have other properties that could delay or prevent regulatory approval.
• Subject to ongoing regulatory compliance obligations and continued regulatory review, resulting in significant additional expense.
• Business activities may be subject to FCPA and similar anti-bribery and anti-corruption laws, as well as export controls, trade sanctions, and import laws.
• Subject to claims challenging the inventorship of patents and other intellectual property.
• Inability to protect the confidentiality of trade secrets.
• Third-party claims of intellectual property infringement, misappropriation, or other violation.
• Involvement in lawsuits to protect or enforce patents and other intellectual property rights.
• Intellectual property rights do not necessarily address all potential threats.
• Reliance on third parties to conduct preclinical studies and clinical trials; third parties may not perform satisfactorily.
• Reliance on third parties for manufacturing product candidates; increases risk of insufficient quality/quantities or unacceptable cost.
• Third-party relationships are important; inability to maintain collaborations or enter new ones could adversely affect business.
• Previously noncompliant with Nasdaq's minimum bid price requirement, risking delisting.
• Incurs additional costs and demands upon management as a result of complying with laws and regulations affecting public companies.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes.
• Does not anticipate paying cash dividends in the foreseeable future.
• Future sales of shares by existing stockholders could cause stock price to decline.
• If equity research analysts do not publish research or reports, or publish unfavorable reports, stock price and trading volume could decline.
• Broad discretion in the use of proceeds from capital raising efforts.
• Principal stockholders and management own a significant percentage of stock and can exert significant control.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future as it advances FB102 through a Phase 2 celiac trial (with topline readout expected in 2026), multiple Phase 1b clinical trials for vitiligo (topline data expected H1 2026) and alopecia areata (topline data expected 2026), and potentially pursues additional autoimmune indications. Future capital requirements are substantial and uncertain, depending on the progress and timing of clinical trials, regulatory approvals, and potential strategic collaborations. The company believes its existing cash and cash equivalents will be sufficient to fund operations for at least 12 months from the filing date of this Form 10-K, but additional funding will be required to complete development and commercialization.

Management Comments

• "We believe that our existing cash and cash equivalents will be sufficient to allow the Company to fund its operations for at least 12 months from the filing date of this Form 10-K."
• "We have been and continue to actively monitor the potential impacts that these various events and circumstances may have on our business and we take steps, where warranted, to minimize any potential negative impacts on our business resulting from these events and circumstances."

Industry Context

StockSavvy.ai notes that Forte Biosciences operates in the highly competitive and rapidly innovating biopharmaceutical industry, characterized by significant R&D investment and strong competition from larger, more resourced companies. The company's focus on autoimmune diseases like celiac disease, vitiligo, and alopecia areata targets substantial and growing markets, with estimated global market sizes for vitiligo ($1.6-1.8 billion in 2024-2025, projected to $2.3-2.7 billion by 2032-2034) and alopecia ($3-3.5 billion in 2024, projected to $6 billion by 2032-2034). The company's reliance on a single lead product candidate (FB102) and its early-to-mid-stage development position it as a high-risk, high-reward player in this space, where successful clinical outcomes and regulatory approvals are critical for market entry and profitability. The recent overruling of the Chevron doctrine by the U.S. Supreme Court introduces additional regulatory uncertainty for the industry, potentially inviting more challenges to FDA decisions.

Comparison to Industry Standards

• The global vitiligo treatment market size was estimated at $1.6-1.8 billion in 2024-2025 and is projected to reach approximately $2.3-2.7 billion by 2032-2034 (Fortune Business Insights), indicating a significant and growing market opportunity for FB102 if approved.
• The global alopecia treatment market has been valued at around $3-3.5 billion in 2024 with some forecasts pointing to the potential to reach $6 billion in 2032-2034 (DataM Intelligence), highlighting another large potential market for FB102.
• Celiac disease affects an estimated 2.5 million people in the U.S., with 0.3% to 0.5% being non-responsive to a gluten-free diet and no approved treatment options, indicating a substantial unmet medical need and market opportunity for FB102.
• Type 1 Diabetes (T1D) affects an estimated 64,000 people diagnosed annually in the U.S., representing another large potential market for FB102's autoimmune applications.
• The company's R&D expenses increased significantly in 2025 ($58.2 million) compared to 2024 ($21.2 million), reflecting typical escalating costs as drug candidates advance into later-stage clinical trials, aligning with industry trends for biopharmaceutical development.

Corporate Governance

Legal Proceedings

• Camac Fund, LP v. Paul A. Wagner, et al. (Del. Ch.): A complaint filed in August 2023 alleging breach of fiduciary duties by directors related to a July 2023 private placement. The company made a $1.5 million payment to Plaintiff's counsel in September 2024, and the case was subsequently closed.
• Forte Biosciences, Inc. v. Camac Fund, LP, et al. (N.D. Tex.): The company filed a complaint in October 2023 alleging false and misleading disclosures by Texas Defendants in connection with director elections. This was settled in October 2024, with the company paying $650 thousand.
• Forte Biosciences, Inc. v. Wesco Insurance Co., et al. (Del. Super. Ct.): The company filed a complaint in October 2024 against its D&O liability insurers for refusal to acknowledge and perform insurance obligations related to the Camac Fund action. The Delaware Superior Court entered judgment in favor of Forte Biosciences on January 8, 2026, finding Wesco Insurance Co. and Palms Insurance Co. liable up to their combined $5 million policy limits. Palms Insurance Co. made an interim payment of $2.3 million in March 2026.
• University of Massachusetts '505 Patent Challenge: Forte filed a petition for post-grant review of U.S. Patent No. 11,278,505 in December 2022. The PTAB found all claims unpatentable in June 2024. The University of Massachusetts filed a request for rehearing in July 2024 (denied October 2024) and a notice of appeal in December 2024, making the outcome of this challenge ongoing.

Related Party Transactions

• One member of the board of directors received $600 thousand for scientific consulting services during the year ended December 31, 2025, and $479 thousand for the same services in 2024.
• Certain executive officers and senior management of the company participated in the November 2024 Private Placement, purchasing $475 thousand in shares of common stock at a price of $5.552 per share.

Stakeholder Impact

• Shareholders: Experience dilution from recent and future equity offerings; face potential for stock price volatility; anti-takeover provisions may limit acquisition opportunities; principal stockholders and management exert significant control over corporate matters.
• Employees: Benefit from equity and cash incentive plans designed to attract, retain, and reward personnel; participate in a 401(k) plan with company match; potential for growth in organization size as the company expands its development efforts.
• Customers/Patients: Potential for new treatment options for celiac disease, vitiligo, alopecia areata, and type 1 diabetes if FB102 is successfully developed and commercialized, addressing significant unmet medical needs.
• Creditors: Ongoing net losses and the need for additional capital may impact creditworthiness, although recent successful capital raises improve short-term liquidity and financial stability.
• Suppliers/CMOs/CROs: The company's reliance on third-party manufacturers and clinical research organizations for development and supply means their performance is critical to the company's success, creating mutual dependency and risk.

Next Steps

• Topline readout expected in 2026 for the Phase 2 celiac study.
• Topline data expected in the first half of 2026 for the Phase 1b non-segmental vitiligo trial.
• Topline data expected in 2026 for the Phase 1b alopecia areata study.
• Continue to conduct additional preclinical studies and clinical trials for FB102 and any future product candidates.
• Seek regulatory approvals for FB102 from the FDA and comparable foreign regulatory authorities.
• Potentially build its own commercial organization or seek collaborations for commercialization of approved products.
• Monitor and manage potential impacts from global and national events (military conflicts, economic uncertainty, inflation, financial institution failures).
• Address the ongoing appeal by the University of Massachusetts regarding the '505 Patent decision.
• Pursue entry of final judgment and payment of prejudgment interest in the legal proceeding against Wesco Insurance Co. and Palms Insurance Co.

Key Dates

Recommendation

Forte Biosciences has demonstrated promising early clinical results for FB102 in celiac disease and has secured substantial funding, which are positive indicators for a clinical-stage biopharmaceutical company. The successful defense of a key patent also reduces a significant intellectual property risk. However, the company continues to incur substantial net losses, has no approved products, and its future is heavily reliant on the successful, lengthy, and expensive development of a single lead product candidate. The inherent uncertainties of clinical trials, regulatory approvals, and future capital requirements suggest that while there is potential, the investment remains speculative. A "hold" recommendation allows seasoned investors to maintain exposure to the upside potential while acknowledging the considerable risks and awaiting further de-risking milestones, such as successful Phase 2 and Phase 3 trial readouts and a clearer path to commercialization.

Keywords

Forte Biosciences, FBRX, biopharmaceutical, clinical-stage, FB102, autoimmune disease, celiac disease, vitiligo, alopecia areata, type 1 diabetes, monoclonal antibody, CD122 antagonist, Phase 1b trial, Phase 2 study, FDA IND approval, drug development, biotech, SEC filing, 10-K, financial results, capital raise, patent litigation, KPMG LLP